Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 3;9(3):1167-1170.
doi: 10.1002/ccr3.3712. eCollection 2021 Mar.

Autologous hematopoietic transplantation following COVID-19 infection

Marthilde Brzycki  1 , Robert Richard  1   2 , Nicholas Burwick  1   2 , Solomon Graf  1   3   4 , Craig O'Brien  1 , Daniel Wu  1   3 , Thomas R Chauncey  1   3   4
Affiliations
Case Reports

Autologous hematopoietic transplantation following COVID-19 infection

Marthilde Brzycki et al. Clin Case Rep. .

Abstract

Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID-19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.

Keywords: COVID‐19; autologous transplantation; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests. No research funding was associated with this report. The subject provided informed consent for treatment and correlative research.

References

    1. Attal M, Lauwers‐Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311‐1320. 10.1056/NEJMoa1611750 - DOI - PMC - PubMed
    1. Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509‐3519. 10.1182/bloodadvances.2020002218 - DOI - PMC - PubMed
    1. Cook G, John Ashcroft A, Pratt G, et al. Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy. Br J Haematol. 2020;190(2):e83‐e86. - PMC - PubMed
    1. Hultcrantz M, Richter J, Rosenbaum C, et al. COVID‐19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234–243. 10.1101/2020.06.09.20126516 - DOI - PMC - PubMed
    1. Lee LYW, Cazier JB, Starkey T, et al. COVID‐19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919‐1926. 10.1016/S1470-2045(20)30442-3 - DOI - PMC - PubMed

Publication types

LinkOut - more resources